Eisai’s David Martin Elected as National Pharmaceutical Council’s Chairman of the Board
For Immediate Release
Contact: Andrea Hofelich, [email protected], 202-827-2078
Washington, D.C. (November 7, 2014)—The National Pharmaceutical Council (NPC) today announced that David J. Martin, Senior Vice President, Market Access and Commercial Services, Eisai Inc., has been elected chairman of its Board of Directors for 2014-15. Mr. Martin has served on NPC’s Board since 2011 and previously held the positions of vice chair and treasurer.
“We’ve benefitted from Dave’s extensive experience and thoughtful approach toward advancing NPC’s research and communications during his tenure on the Board,” said NPC President Dan Leonard. “We look forward to his leadership in helping us address health policy challenges such as ensuring patient access to medicines, especially in today’s changing delivery and reimbursement environment.”
Mr. Martin has had an extensive and successful career with a number of key pharmaceutical organizations, including Johnson & Johnson, Pharmacia (now part of Pfizer Inc.) and Wolters Kluwer, where he progressed through roles of increasing responsibility within sales, sales management, marketing management and general management. He has been with Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., for more than five years, where he currently serves as the company’s senior leader for its business-to-business interactions with Eisai’s major segments and customers, as well as leads the commercial services teams.
"I am honored to be elected chairman of NPC's Board of Directors," Martin said. "Through its many research and education initiatives, NPC continues to play a vital role in bringing critical health policy issues to the forefront, all in an effort to support an environment in which medical innovation flourishes. I look forward to working with my fellow board members in the year ahead to further NPC’s mission.”
The NPC Board also elected Steven J. Romano, MD, Senior Vice President and Head, Global Medicines Development, Global Innovative Pharmaceuticals Business, Pfizer Inc., as Vice Chair; Mike Derkacz, Vice President and General Manager, CNS Business Unit, Teva Pharmaceuticals, as Treasurer; and Richard H. Bagger, Senior Vice President, Corporate Affairs and Strategic Market Access, Celgene, and Jeff Huth, Senior Vice President, Managed Markets, Boehringer Ingelheim Pharmaceuticals Inc., and immediate past NPC chairman, to serve on the executive committee.
About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.
# # #